Question 1

What are the potential benefits of participating in this trial compared to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis clinical trial (NCT06330077). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I be aware of with Ifenprodil?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis clinical trial (NCT06330077). Contact the study team or your healthcare provider for specific answers.

Question 3

How often will I need to visit the clinic during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis clinical trial (NCT06330077). Contact the study team or your healthcare provider for specific answers.

Question 4

What tests or procedures will I need to undergo if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis clinical trial (NCT06330077). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any risks involved in participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis clinical trial (NCT06330077). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my health be monitored throughout the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis clinical trial (NCT06330077). Contact the study team or your healthcare provider for specific answers.

What this study is about